When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. List of hematologic conditions - Wikipedia

   en.wikipedia.org/wiki/List_of_hematologic_conditions

   This is an incomplete list, which may never be able to satisfy certain standards for completion. There are many conditions of or affecting the human hematologic system—the biological system that includes plasma, platelets, leukocytes, and erythrocytes, the major components of blood and the bone marrow. [1]

3. Category:Rare cancers - Wikipedia

   en.wikipedia.org/wiki/Category:Rare_cancers

   Pages in category "Rare cancers" The following 110 pages are in this category, out of 110 total. This list may not reflect recent changes. A. Acanthoma; Adamantinoma;

4. Myeloproliferative neoplasm - Wikipedia

   en.wikipedia.org/wiki/Myeloproliferative_neoplasm

   Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.

5. List of cancer types - Wikipedia

   en.wikipedia.org/wiki/List_of_cancer_types

   The following is a list of cancer types. Cancer is a group of diseases that involve abnormal increases in the number of cells, with the potential to invade or spread to other parts of the body. [1] Not all tumors or lumps are cancerous; benign tumors are not classified as being cancer because they do not spread to other parts of the body. [1]

6. US FDA gives second approval to Eli Lilly's drug for type of ...

   www.aol.com/news/us-fda-gives-second-approval...

   Jaypirca was first given accelerated approval by the FDA on Jan. 27 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to ...

7. US FDA approves Citius' therapy for rare blood cancer - AOL

   www.aol.com/news/us-fda-approves-citius-blood...

   The therapy, called Lymphir, is approved to treat certain adult patients with relapsed cutaneous T-cell lymphoma, a group of rare blood cancers that affects the skin. About 2,500-3,000 patients ...